| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
02-20-2009, 02:21 AM
|
#1 | |||
|
||||
|
Senior Member
|
Press Release
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA Jerusalem, Israel and Lund, Sweden, February 12, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. Food and Drug Administration (FDA). Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod (ALLEGRO) in November 2008 and is currently enrolling RRMS patients globally for the second Phase III study (BRAVO). to read the full report please go to http://www.tevapharm.com/pr/2009/pr_823.asp I wonder what the cost of a daily pill will be? Can't be the same as injectables, can it? It is so far just for those with RRMS.
__________________
LADY May happiness be at your door. May it knock early, stay late, and leave the gift of good health behind. "Life is what it is". We can only focus on controlling those things we can control, we must let go of the things we can't. Last edited by Chemar; 02-21-2009 at 01:48 PM. Reason: copyright |
|||
|
 Reply With Quote
|
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Neurologix Gene Therapy Approach to Parkinson's Disease Granted Fast Track by FDA | Parkinson's Disease | |||
| Trophos Granted Orphan Drug Status For Tro19622 | ALS News & Research | |||
| Trophos Granted Orphan Drug Status for TRO19622 | ALS News & Research | |||
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Threaded Mode